Selective mode antimicrobial resistance therapeutics
Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance.
Focus on high revenue segment - patients in hospitals.
Products, services, technology
With our 3 preclinical assets we perform the lead optimization, full pharmacological profiling, and pharmacodynamic efficacy studies in rodent and none-rodent mammalian animal models are our objectives towards a fully characterized pre-clinal IND candidates.
Cooperation possibilities
With our first-in-class antiinfectives, we perform R&D of new mechanism of action antibiotics by 3 new modalities in-vivo active against fungi or bacteria.
Active against multi-resistant clinical isolates in infection in-vivo studies and are based on new IP-protected chemical modalities.
- http://www.selmod.com
- +41 76 734 14 89
- Send an email
- Frank Gombert
Some insights
We provide life saving 2nd-line and last resort antibiotics overcoming antimicrobial resistant (AMR) infections.
Cancer, organ transplant and immune-compromised patients have a high recurring risk of infections promoting the formation of resistance.
I am happy to share my idea with a highly motivated team of pharmaceutical drug R&D professionals and managers empowered to commit their knowledge, experience and creativity to progress disruptive innovations towards the next clinical inflection milestone addressing a critical unmet disease issue.
Entrepreneurs assembling and leading a creative team with disruptive ideas and concepts towards a successful market entry.
The founder and leadership team is highly motivated to support our disruptive therapeutic projects towards success. We combine experiences and skills needed in the initial stage of our startup.
While growing we offer project management, regulatory, clinical study management and finances.
They are impressed by my perseverance and endurance to work in pharmaceutical drug research and development on new projects.
Networking, new contacts to financial support and CROs.
Private investors, family offices and foundations.
Institutional and venture capital investors.
